Sopharma AD is planning the establishment of two new subsidiaries, which will later be listed on the stock exchange. These are Sopharma Building and Doverie Properties, CEO Ognyan Donev said yesterday at the forum on the Future Of Capital Markets In Southeast Europe.

“Two other companies – Unipharm and Sopharma Trading, are planning to file public offerings this year, or in the first months of 2008,” Mr. Donev also said.

Asked about the company's recent acquisitions of stakes in other public enterprises, Donev said the deals were the result of Sopharma's efforts to consolidate its business.

“As far as Lavena is concerned, this is just a portfolio investment, while the acquisition in Momina Krepost was a strategic one,” Donev added. Ognyan Donev has been CEO of the pharmaceutical company for seven years.

Sopharma AD currently produces 210 products and exports to 28 countries.

The company received a First Class Investor Certificate last week. Sopharma is planning to build a new modern plant for the production of tablets.

The plant will be built in Sofia, on a plot near the company's ampullas plant on 16 Iliensko Shose Str. It is planned as a compact ensemble of buildings – a production building, a packaging building, a warehouse, an administrative building, and a laboratory. The plant will cover an area of 8,966 sq m on a land plot owned by Sopahrma. Total built-up area will be 13,502 sq m.

275 people will be employed in the new plant. The total value of the investment stands at 37.65 mln euros.

Sopharma posted a net consolidated profit in the amount of 20.013 mln leva (10.232 mln euros) in 2007 H1, versus 15.978 mln leva (8.169 mln euros) a year ago.

The stock was traded at levels between 7.61 and 7.78 leva yesterday.